Keros Therapeutics said it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.

The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension.

Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.

The company expects to present clinical data from the trial in the second quarter of 2025.